Trade Names:Maxitrol- Ophthalmic Suspension 0.1% dexamethasone, neomycin sulfate equivalent to 0.35% neomycin base, and 10,000 units/mL polymyxin B sulfate
Inhibits protein synthesis by binding to ribosomal RNA, causing bacterial genetic code misreading.Polymyxin B
Interacts with phospholipid components of bacterial cell membranes, increasing cell wall permeability.Dexamethasone
Depresses formation, release, and activity of endogenous mediators of inflammation including prostaglandins, kinins, histamine, liposomal enzymes, and complement systems.
Treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists; inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation; chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies; when risk of infection is high or where there is expectation that potentially dangerous numbers of bacteria will be present in the eye.
Epithelial herpes simplex keratitis (dendritic keratitis), vaccine, vericella, and many other viral diseases of the corneal and conjunctiva; mycobacterial eye infections; fungal diseases of the ocular structures; uncomplicated removal of a corneal foreign body; hypersensitivity to any component of the product.
Ophthalmic Suspension Instill 1 or 2 drops into the conjunctival sac(s) up to 4 to 6 times/day in mild disease. In severe disease, drops may be used hourly, tapering to discontinuation as the inflammation subsides.
Store at controlled room temperature (59° to 86°F). Keep bottle or tube tightly capped.
None well documented.
None well documented.
Elevated IOP with possible development of glaucoma; optic nerve damage; posterior subcapsular cataract formation; delayed wound healing; secondary infection; fungal infection.
Category C .
Safety and efficacy have not been established.
Prolonged use may result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Ensure that IOP is measured if therapy is continued beyond 10 days.
Secondary bacterial ocular infection following suppression of host responses may occur.
Copyright © 2009 Wolters Kluwer Health.